ImmunityBio IBRX
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 28th percentile, 5-year average -5.5x
Around its usual level · 41st percentile, 5-year average -6.1x
Near the bottom of its 5-year range · 9th percentile, 5-year average 2,386.3x
#4830 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -5.58 | – | -6.15 | 41% (cheaper than usual) | – |
| PE | -5.68 | -15.71 | -5.48 | 28% (cheaper than usual) | – |
| PS | 35.08 | 21.42 | 2,386.29 | 9% (cheaper than usual) | #4830 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on IBRX.
Sign in to join the discussion.